Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesHigh expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma
British Journal of Cancer, 04/10/09
Maréchal R et al. - In a study to determine pts' outcome according to the expressions of CXCR4, CXCR7 and HIF-1α after resection of pancreatic adenocarcinoma (PA), it was shown that CXCR4 in resected PA may represent a valuable prognostic factor as well as an attractive target for therapeutic purpose.
Methods- Immunohistochemistry for CXCR4, CXCR7 and HIF-1α expressions as well as cell proliferative index (Ki-67) was conducted in 71 resected (R0) PA and their 48 related lymph nodes (LN) using tissue microarray.
- CXCR4 and CXCR7 expressions were positively correlated to HIF-1α suggesting a potential role of HIF-1α in CXCR4 and CXCR7 transcription activation.
- Pts with CXCR4high tumour expression had shorter OS than those with low expression (median survival: 9.7 vs 43.2 mos), a higher risk of LN metastases and liver recurrence.
- In multivariate analysis, high CXCR4 expression, LN metastases, and poorly differentiated tumour are independent negative prognosis factors.
- In a combining analysis, pts with CXCR4low/CXCR7low tumour had a significantly shorter DFS and OS than pts with a CXCR7high/CXCR4high tumour.
Related Articles
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma
European Journal of Surgical Oncology, 11/18/09
Relevance Score: 79%
Preoperative Diabetes Mellitus and Long-Term Survival After Resection of Pancreatic Adenocarcinoma
Annals of Surgical Oncology, 11/09/09
Relevance Score: 79%
Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling
Cancer Science, 10/28/09
Relevance Score: 79%
HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment
Expert Review of Anticancer Therapy, 10/26/09
Relevance Score: 79%
Resectable Pancreatic Adenocarcinoma: Is the Enhancement Pattern at Contrast-Enhanced Ultrasonography a Pre-Operative Prognostic Factor
Ultrasound in Medicine and Biology, 10/16/09
Relevance Score: 79%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Association between global DNA hypomethylation in leukocytes and risk of breast cancer
Carcinogenesis, 11/30/09
The Rac1/MKK7/JNK pathway signals upregulation of Atg5 and subsequent autophagic cell death in response to oncogenic Ras
Carcinogenesis, 11/30/09
The extracellular loop 2 of TM4SF5 inhibits integrin alpha2 on hepatocytes under collagen type I environment
Carcinogenesis, 11/30/09
Today in Endocrine Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Neuroendocrine carcinomas arising in solid-organ transplant recipients: rare but aggressive malignancies
Oncology (Karger), 11/25/09
Malignant teratoma of the thyroid in a pregnant woman
Annals of Diagnostic Pathology, 11/23/09
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
European Journal of Endocrinology, 11/19/09
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer
Carcinogenesis, 11/30/09
Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins
Blood, 11/30/09
Sorafenib in patients with advanced biliary tract carcinoma: A phase II trial
British Journal of Cancer, 11/30/09
Sponsor
Article Search
Sponsor
Sponsor